Cancer is the second most frequent cause of death worldwide, with 28.4 million new cases
expected for 2040. Despite de advances in the treatment, it remains a challenge because of …

Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors in the
contemporary era, representing a significant global health concern. Early HCC patients have …

Background In past few decades, the research on engineered nanocarriers (NCs) has
gained significant attention in cancer therapy due to selective delivery of drug molecules on …

RNA therapy is a disruptive technology comprising a rapidly expanding category of drugs.
Further translation of RNA therapies to the clinic will improve the treatment of many diseases …

Targeted extrahepatic delivery of siRNA remains a challenging task in the field of nucleic
acid therapeutics. An ideal delivery tool must internalize siRNA exclusively into the cells of …

New boron carriers with high boron content and targeted cancer-cell delivery are considered
the first choice for boron neutron capture therapy (BNCT) for cancer treatment. Previously …

Nanotheranostic‐based photochemotherapies with targeted drug delivery have
considerably surfaced in cancer therapy. In the presented work, polyethyleneimine‐coated …

Genomic and proteomic mutation analysis is the standard of care for selecting candidates for
therapies with tyrosine kinase inhibitors against the human epidermal growth factor receptor …

Liver cancer is one of the most common malignancies worldwide. The RAF kinase inhibitors
are effective in the treatment of hepatocellular carcinoma (HCC); therefore, inhibition of the …

In the biomedical industry, nanoparticles (NPs—exclusively small particles with size ranging
from 1–100 nanometres) are recently employed as powerful tools due to their huge potential …